Journal of Molecular Oncology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Journal of Molecular Oncology Research (2025) Volume 9, Issue 2

Targeting cancer stem cells: A new frontier in molecular oncology research

Olga Martinho *

Department of Life and Health Sciences, University of Minho, Portugal

*Corresponding Author:
Olga Martinho
Department of Life and Health Sciences, University of Minho, Portugal
E-mail: olga.martinho@uminho.pt

Received: 01-May-2025, Manuscript No. AAMOR -25-166708; Editor assigned: 02-May-2025, PreQC No. AAMOR -25-166708(PQ); Reviewed: 18-May-2025, QC No. AAMOR -25-166708; Revised: 22-May-2025, Manuscript No. AAMOR -25-166708(R); Published: 29-May-2025, DOI: 10.35841/ aamor-9.2.289

Citation: : Martinho O. Targeting cancer stem cells: A new frontier in molecular oncology research. J Mol Oncol Res. 2025;9(2):289.

Visit for more related articles at Journal of Molecular Oncology Research

Introduction

Cancer remains a formidable challenge in medicine due to its complexity, heterogeneity, and propensity for relapse and metastasis. Central to these challenges is the concept of cancer stem cells (CSCs) a specialized subpopulation within tumors characterized by self-renewal, differentiation capacity, and resistance to conventional therapies. Over the past decade, molecular oncology research has increasingly focused on CSCs as critical drivers of tumor initiation, progression, and treatment failure. Understanding and targeting CSCs offers a promising strategy to improve cancer outcomes and achieve durable remissions [1].

The Biology and Role of Cancer Stem Cells in Tumor Progression. Cancer stem cells share many features with normal stem cells, including the ability to self-renew and give rise to diverse cell types within a tumor. These properties allow CSCs to sustain tumor growth and contribute to intratumoral heterogeneity. Moreover, CSCs are often more resistant to chemotherapy and radiation than the bulk of tumor cells, due to enhanced DNA repair mechanisms, drug efflux capacity, and quiescence. CSCs have been identified in a variety of solid tumors and hematologic malignancies. Their presence correlates with aggressive disease phenotypes, metastatic potential, and poor patient prognosis. By evading traditional treatments, CSCs can survive therapy and seed tumor recurrence, highlighting their crucial role in cancer persistence [2].

Advances in Molecular Oncology Research Targeting CSCs. Recent advances in molecular oncology have shed light on signaling pathways and molecular markers that regulate CSC biology, including Wnt/β-catenin, Notch, Hedgehog, and PI3K/Akt pathways. These pathways govern CSC maintenance and survival, making them attractive therapeutic targets. Innovative therapeutic strategies are being developed to selectively eliminate CSCs. These include small molecule inhibitors, monoclonal antibodies, and immunotherapies aimed at disrupting CSC-specific pathways or surface markers. Additionally, researchers are exploring the tumor microenvironment’s role in supporting CSCs and designing treatments that modify this niche to reduce CSC survival [3].

Challenges in Targeting Cancer Stem Cells. Despite exciting progress, several challenges remain in translating CSC research into effective clinical therapies. CSCs exhibit significant plasticity, with non-stem tumor cells sometimes acquiring stem-like properties under stress or treatment pressure. This dynamic nature complicates the identification of stable CSC markers and therapeutic targets [4].

Furthermore, CSCs often reside in protective niches that limit drug penetration, requiring combination therapies or novel delivery systems to reach these cells effectively. The potential toxicity of CSC-targeting agents on normal stem cells also demands careful design to minimize adverse effects.

Future Directions and Clinical Implications. Molecular oncology research is increasingly leveraging high-throughput genomics, single-cell sequencing, and advanced bioinformatics to dissect CSC heterogeneity and uncover novel vulnerabilities. Integrating these data with patient-derived models accelerates the identification of personalized therapies aimed at CSCs. Clinical trials testing CSC-targeted agents, alone or in combination with conventional therapies, are ongoing and show promising early results. Success in this field could shift cancer treatment paradigms from simply shrinking tumors to eradicating the root causes of recurrence and metastasis [5].

Conclusion       

Cancer stem cells represent a pivotal focus in molecular oncology research, holding the key to overcoming treatment resistance and improving long-term outcomes. Advances in understanding CSC biology and therapeutic targeting offer hope for more effective and lasting cancer treatments. While challenges persist, continued interdisciplinary research and clinical innovation are essential to fully realize the potential of CSC-directed therapies in transforming cancer care.

References

  1. Bárcena C, Quirós PM, Durand S, et al. Methionine restriction extends lifespan in progeroid mice and alters lipid and bile acid metabolism. Cell Rep. 2018; 24:2392-403.

    2. Indexed at, Google Scholar, Cross Ref

  2. Bi J, Chowdhry S, Wu S, et al. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer. 2020; 20:57-70.

    3. Indexed at, Google Scholar, Cross Ref

  3. Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Sci. 2017; 358:1443-448.

    4. Indexed at, Google Scholar, Cross Ref

  4. Collins D, Hogan AM, Winter DC, et al. Microbial and viral pathogens in colorectal cancer. Lancet Oncol. 2011; 12:504-12.

    5. Indexed at, Google Scholar, Cross Ref

  5. De Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019; 381:2541-2551.

    6. Indexed at, Google Scholar

  6. Armstrong GT, Stovall M, Robison LL, et al. Long-term effects of radiation exposure among adult survivors of childhood cancer: Results from the childhood cancer survivor study. Radiat Res. 2010;174:840-50.

    7. Indexed at, Google Scholar, Cross Ref

  7. Mostoufi-Moab S, Seidel K, Leisenring WM, et al. Endocrine abnormalities in aging survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol. 2016; 34:3240-47.

    8. Indexed at, Google Scholar

  8. Geenen MM, Bakker PJM, Kremer LCM, et al. Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer. 2010; 55:690-97.

    9. Indexed at, Google Scholar, Cross Ref

  9. Neville KA, Cohn RJ, Steinbeck KS, et al. Hyperinsulinemia impaired glucose tolerance and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab. 2006;91:4401-07.

    10. Indexed at, Google Scholar, Cross Ref

  10. Cicognani A, Cacciari E, Mancini AF, et al. Abnormal insulin response to glucose following treatment for Wilms’ tumor in childhood. Eur J Pediatr.1997; 156:371-75.

    11. Indexed at, Google Scholar, Cross Ref

Get the App